menu
    • menu
    [{"orgOrder":0,"company":"Brise Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BR01T","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brise Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brise Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Brise Pharma","sponsor":"Shunxi Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"BR01T","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brise Pharma \/ Shunxi Fund","highestDevelopmentStatusID":"6","companyTruncated":"Brise Pharma \/ Shunxi Fund"}]

    Find Clinical Drug Pipeline Developments & Deals by Brise Pharma

    Menu

    Brise Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Brise Pharma

                            China arrow
                            APS Symposium
                            Not Confirmed

                            Brise Pharma

                            China arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BR01T

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Shunxi Fund

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Brise Pharmaceuticals Raises Nearly $20M in Series Pre-A and Pre-A+ Financing

                            Details : Proceeds will support the development of BR01T, an anti-TrkA antibody with potential to revolutionize chronic low back pain treatment, as the company advances its product pipeline.

                            Product Name : BR01T

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : BR01T

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Shunxi Fund

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Brise Pharma

                            China arrow
                            APS Symposium
                            Not Confirmed

                            Brise Pharma

                            China arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BR01T

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Brise Pharma Announces First Patient Dosed with BR01T in Phase I Study in Patients with Chronic Low Back Pain

                            Details : BR01T, is a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA), which is investigated for addressing Chronic Low Back Pain (CLBP).

                            Product Name : BR01T

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : BR01T

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth